Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder
Introduction The efficacy and of current antidepressants is insufficient. Esketamine, a new antidepressant administered by nasal route, is available since 2019 in the management of resistant characterized depressive episodes. Objectives To evaluate the response profile of patients to Esketamine in...
Furkejuvvon:
| Váldodahkkit: | , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Cambridge University Press
2022-06-01
|
| Ráidu: | European Psychiatry |
| Fáttát: | |
| Liŋkkat: | https://www.cambridge.org/core/product/identifier/S0924933822014171/type/journal_article |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|